Innate Pharma tumbles 14% after disappointing announcement
Innate Pharma stock plummets 14% after investors deem announcement disappointing.
Published 12sem1 sourceNotable
Lire en français
≈ 16s
The fact
Market's sharp reaction reflects major disappointment over clinical or commercial prospects.
Fall illustrates volatility and sensitivity of biotech stocks to results and announcements.
Click the link to read an article on the topic:
Observed impact
Capitalisation de la biotech en recul significatif